全球 mRNA 治療市場規模、佔有率、成長分析，依類型（預防性疫苗、治療性疫苗）、依應用（罕見遺傳疾病、腫瘤）- 2024-2031 年產業預測

2022年全球MRNA治療市場規模為408.0億美元，預計將從2023年的416.2億美元成長到2031年的487.6億美元，預測期間（2024-2031年）CAGR為2%。

基於 mRNA 的療法作為一種有效治療慢性病的有前途的解決方案最近受到了極大的關注，從而促使市場的穩定和有保障的成長。近年來，mRNA疫苗因其在生產和分銷方面的優勢而比DNA疫苗受到青睞，提供了更安全的替代方案。這些疫苗和療法已成功進行人體臨床試驗，進一步增加了對這些產品的需求。 Moderna 和 Pfizer-BioNTech 等公司在市場上發揮了重要作用，特別是在 COVID-19 大流行期間。他們為應對全球健康危機而開發的疫苗極大地推動了市場成長。 mRNA療法也主要用於腫瘤臨床試驗，2021年針對癌症患者的mRNA疫苗試驗吸引了大量志願者，參與度排名第二，不包括針對癌症患者的COVID-19試驗。自那時以來，該行業見證了顯著的成長。全球範圍內 SARS-CoV-2 病毒新變種的出現強調了對有效疫苗的需求，促使醫療專業人員轉向 mRNA 疫苗。 COVID-19 大流行加速了基於 mRNA 的產品的利用，進一步推動了市場擴張。由於採用提高翻譯和穩定性的技術進步以及遞送技術，信使 RNA 已成為一種強大的治療工具。製藥業認知到 mRNA 疫苗的擴張潛力，顯示該市場的成長前景廣闊。 mRNA 疫苗代表了疫苗開發的下一個階段，開創了免疫的新時代。一個很好的例子是Moderna Inc. 與美國國家過敏和傳染病研究所之間的合作，最終於2020 年3 月創建了mRNA-1273 (NIAID)。 % 的有效率-19，於2020年12月獲得美國FDA的快速批准和緊急使用授權。增加對基於mRNA的產品的需求未來。

目錄

執行摘要

• 市場概況
• 命運之輪

研究方法論

• 資訊採購
• 二手和主要資料來源
• 市場規模估計
• 市場假設與限制

母公司市場分析

• 市場概況
• 市場規模
• 市場動態
  • 促進要素
  • 機會
  • 限制
  • 課題

主要市場洞察

• 技術分析
• 定價分析
• 供應鏈分析
• 價值鏈分析
• 市場生態系統
• 智慧財產權分析
• 貿易分析
• 啟動分析
• 原料分析
• 創新矩陣
• 管道產品分析
• 總體經濟指標
• 頂級投資分析
• 成功的關鍵因素
• 競爭程度

市場動態與展望

• 市場動態
  • 促進要素
  • 機會
  • 限制
  • 課題
• 監管環境
• 波特分析
• 對未來顛覆的特別見解

依類型分類的全球 mRNA 治療市場

• 市場概況
• 預防性疫苗
• 治療性疫苗
• 治療藥物

全球 mRNA 治療市場（依應用）

• 市場概況
• 罕見遺傳疾病
• 腫瘤學
• 呼吸疾病
• 傳染性疾病
• 其他

全球 mRNA 治療市場規模（依地區）

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 拉丁美洲其他地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • MEA 的其餘部分

競爭格局

• 前 5 名企業比較
• 2021 年關鍵參與者的市場定位
• 主要市場參與者所採取的策略
• 最佳制勝策略
• 近期市集活動
• 主要公司市佔率（%），2021年

主要公司簡介

• CureVac AG (Germany)
• Roche Holding AG (Switzerland)
• Pfizer Inc. (USA)
• GlaxoSmithKline plc (United Kingdom)
• Moderna, Inc. (USA)
• Sanofi SA (France)
• BioNTech SE (Germany)
• Dynavax Technologies Corporation (USA)
• Arcturus Therapeutics Holdings Inc. (USA)
• AstraZeneca plc (United Kingdom)
• Regeneron Pharmaceuticals, Inc. (USA)
• Alnylam Pharmaceuticals, Inc. (USA)
• Gilead Sciences, Inc. (USA)
• Mylan NV (USA)
• Novartis AG (Switzerland)
• Modulus Therapeutics, Inc. (USA)
• Catalent, Inc. (USA)
• Translate Bio, Inc. (USA)
• Ionis Pharmaceuticals, Inc. (USA)
• Vertex Pharmaceuticals Incorporated (USA)

Global MRNA Therapeutics Market size was valued at USD 40.80 Billion in 2022 and is poised to grow from USD 41.62 Billion in 2023 to USD 48.76 Billion by 2031, at a CAGR of 2% during the forecast period (2024-2031).

mRNA-based therapeutics have recently gained significant attention as a promising solution for effectively treating chronic conditions, leading to the steady and assured growth of the market. In recent times, mRNA vaccines have become preferred over DNA vaccines due to their advantages in production and distribution, offering a safer alternative. These vaccines and therapeutics have successfully undergone human clinical trials, further boosting demand for these products. Companies like Moderna and Pfizer-BioNTech have played a major role in the market, particularly during the COVID-19 pandemic. Their vaccines developed in response to the global health crisis significantly fueled market growth. mRNA therapeutics are also prominently used in oncology clinical trials, with mRNA vaccine trials for cancer patients in 2021 attracting a substantial number of volunteers, ranking second highest in participation, excluding COVID-19 trials in cancer patients. The industry has witnessed remarkable growth since then. The emergence of new variants of the SARS-CoV-2 virus worldwide has emphasized the need for effective vaccines, prompting medical professionals to turn to mRNA vaccines. The COVID-19 pandemic accelerated the utilization of mRNA-based products, further driving market expansion. Messenger RNA has emerged as a powerful therapeutic tool, thanks to technological advancements that improve translation and stability, as well as delivery techniques. The pharmaceutical industry recognizes the potential for expansion through mRNA vaccines, indicating promising growth prospects for the market. mRNA vaccines represent the next stage in vaccine development, ushering in a new era in immunization. An excellent example of this is the collaboration between Moderna Inc. and the National Institute of Allergy and Infectious Diseases, which resulted in the creation of mRNA-1273 (NIAID) in March 2020. This vaccine demonstrated a 94.1% efficacy rate in preventing symptomatic COVID-19, receiving expedited approval from the US FDA and emergency use authorization in December 2020. Furthermore, the rapidly expanding field of mRNA therapeutics is set to revolutionize personalized medicine, transforming traditional healthcare standards and increasing the demand for mRNA-based products in the foreseeable future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global MRNA Therapeutics and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Global MRNA Therapeutics Market Segmental Analysis

The global mRNA therapeutics market is segmented on the basis of type, application, region. By type, the market is segmented into prophylactic vaccines, therapeutic vaccines, therapeutic drugs. By application, the market is segmented into rare genetic diseases, oncology, respiratory diseases, infectious diseases, others. By end-use, the market is segmented into hospitals & clinics, research organizations, others. By region, the market is segmented into North America, Europe, Latin America, Asia- Pacific, Middle East and Africa.

Drivers of the Global MRNA Therapeutics Market

The COVID-19 pandemic accelerated the development of mRNA vaccines, highlighting mRNA technology's effectiveness in fighting infectious diseases.

Growing investments from public and private sectors, such as government agencies and venture capital firms, are fuelling research and development (R&D) activities in mRNA therapies.

An increase in clinical trials for a range of illnesses, including cancer, rare genetic disorders, and infectious diseases, is driving the market's growth.

Restraints in the Global MRNA Therapeutics Market

The global market for mRNA therapeutics encountered several challenges, particularly in the production and distribution processes. Scaling up mRNA production capacity while maintaining a stable supply chain was notably challenging, especially during a global health crisis.

There are inherent risks in mRNA therapeutics, requiring extensive testing, experimentation, and analysis. Concerns arise regarding potential immune responses or off-target effects, which could pose safety risks in the future and potentially impede market growth.

The mRNA therapeutics market faces competition from emerging technologies and established treatments that offer similar benefits without the potential safety concerns. These alternative therapies pose a threat to the growth of the mRNA therapeutics market.

Market Trends of the Global MRNA Therapeutics Market

mRNA Cancer Vaccines: The market for mRNA cancer vaccines is experiencing a notable and impactful trend. The development of cancer vaccines using mRNA technology presents a significant opportunity for advancements in oncology treatment and therapy.

Partnerships and Collaborations: Another prevailing trend in the market and related industries is the increasing focus on mRNA product development and the rise in expertise within the field. This is largely due to the growing number of collaborations and mergers among global pharmaceutical companies.

Orphan Diseases: The market has also witnessed the emergence of a significant trend involving the treatment of rare diseases. The therapeutics offered by this market have the potential to address medical needs that have previously gone untreated, particularly in the realm of orphan diseases. As a result, mRNA therapies are gaining increased attention from medical professionals and patients alike.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global mRNA Therapeutics Market by Type

• Market Overview
• Prophylactic Vaccines
• Therapeutic Vaccines
• Therapeutic Drugs

Global mRNA Therapeutics Market by Application

• Market Overview
• Rare Genetic Diseases
• Oncology
• Respiratory Diseases
• Infectious Diseases
• Others

Global mRNA Therapeutics Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• CureVac AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dynavax Technologies Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arcturus Therapeutics Holdings Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Modulus Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Translate Bio, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments